Key takeaways
- 1Alternate-day self-dosing of a disease-modifying therapy is not a cost strategy — it risks rebound disease activity and required urgent neurologist input.
- 2Applying for assistance first, in parallel with verifying a same-salt option, gave continuity without a treatment gap.
- 3MRI at six months confirmed no new lesion activity — objective confirmation that the switch preserved control.
- 4Even a partial assistance approval buys the window to arrange a sustainable long-term route calmly.
Case snapshot
- Patient profile
- Composite profile — 34-year-old with relapsing-remitting MS
- Country
- United States
- Condition
- Relapsing-remitting multiple sclerosis
- Medicine
- Fingolimod 0.5 mg daily
Western cost
~$96,000 per year
Reference alternative
~$1,140 per year reference
Impact
~$94,860 per year
On this page
1The problem with lifelong therapy
Disease-modifying therapy in relapsing MS is not a course. It continues for years, often decades, to reduce relapse frequency and slow disability accumulation.
That changes the arithmetic entirely. A cost that is merely painful for twelve weeks becomes structurally impossible over twenty years. At list pricing, two decades of one oral disease-modifying therapy approaches two million dollars.
The patient in this profile was insured, but a plan change moved her therapy to a specialty tier with coinsurance that made continuation unaffordable. She had begun taking the capsule every other day.
2The options her neurologist laid out
Rather than a single answer, the neurologist presented four routes and their trade-offs. This is the conversation worth replicating.
| Option | Annual cost | Trade-off |
|---|---|---|
| Continue branded fingolimod | ~$96,000 | Financially impossible |
| Manufacturer assistance programme | $0 if approved | Income tested; approval not guaranteed |
| Switch to a different DMT class | Varies widely | Requires washout and new risk profile |
| Same-salt generic fingolimod | ~$1,140 reference | Requires verification and supervision |
3The process followed
The assistance programme application was submitted first, because a free supply from the originator would have been the simplest outcome. While it was pending, the correct daily dose was restored using existing stock.
- 1Correct daily dosing restored immediately — the alternate-day pattern stopped that week.
- 2Manufacturer assistance application submitted with the clinic's help.
- 3Manufacturer verification carried out for the generic option in parallel.
- 4Baseline bloods, liver function and ophthalmological assessment documented before any change.
- 5Cardiac monitoring arrangements confirmed, as required for this agent class.
- 6MRI scheduled at six months to compare lesion activity objectively.
4Outcome
The assistance application was partially approved, covering a defined period. She used that window to complete verification of a same-salt option with her neurologist so that continuity was assured when the assistance period ended.
At six months, MRI showed no new lesion activity and she had experienced no relapse. Crucially, she had taken her therapy every single day for the first time in eight months.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Statistics alone cannot carry the weight of a decision about medicine. A line like 'the same course is 340 times cheaper' means nothing until you can see what it did to one household's bills, monitoring schedule and peace of mind.
The only reason we show any switch is to illustrate a pattern. Your own move must be planned with your prescriber.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
What the Jivan dataset shows
- 94×
- average price gap Neurology
- 87.9%
- of anchors exceed 10×
- 282×
- widest documented gap
Across our Neurology anchors, 33 referenced molecules average a 94× price gap, 87.9% of them are at least 10× cheaper in India, and the widest documented comparison is Clobazam at 282×. Across Neurology anchors, disease-modifying oral therapies show some of the largest absolute annual gaps in the dataset because the savings compound over years of continuous dosing.
Computed live from 33 anchors
Frequently asked questions
Stopping should only ever be a neurologist's decision. Some agents carry a risk of rebound disease activity after discontinuation, and unplanned interruption can allow relapse.
Several oral disease-modifying therapies including fingolimod, dimethyl fumarate and teriflunomide now have generic versions in various markets. Injectable and infused biologics follow the biosimilar pathway instead.
It depends on the agent, but typically baseline and follow-up bloods, liver function, specific cardiac or ophthalmological checks for certain drugs, and interval MRI to assess disease activity objectively.
Sources and further reading
Every factual claim above is traceable to a public primary source. We cite regulators and public health bodies rather than commercial sellers.
- 1Generic and Hybrid MedicinesEuropean Medicines Agency
- 2Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)U.S. Food & Drug Administration
- 3MedlinePlus Drug InformationU.S. National Library of Medicine
- 4Health Costs and Prescription Drug ResearchKFF (Kaiser Family Foundation)
How this article was made
Written and researched
Pricing Research Editor, Jivan Editorial TeamEditorially reviewed
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Important medical safety notice
Always consult a licensed physician before changing medicine, dose, or brand. Jivan provides educational pricing intelligence and does not replace emergency or diagnostic care.